Abstract
Leukemia inhibitory factor (LIF) is a survival factor for motoneurons. In this study we investigated whether intense systemic LIF therapy prevents the loss of lumbar motoneurons in the transgenic SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. Treatment involved daily 25 microg/kg intraperitoneal injection for a period of 6 weeks starting at 70 days of age. Using the unbiased optical dissector technique, significant rescue of motoneurons in the LIF-treated group (3809+/-455) was found compared to the vehicle group (1085+/-140).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amyotrophic Lateral Sclerosis / drug therapy*
-
Amyotrophic Lateral Sclerosis / pathology*
-
Animals
-
Cachexia / chemically induced
-
Cachexia / pathology
-
Cell Count
-
Cell Survival / drug effects
-
Growth Inhibitors / administration & dosage
-
Growth Inhibitors / pharmacology*
-
Growth Inhibitors / toxicity
-
Humans
-
Injections, Intraperitoneal
-
Interleukin-6*
-
Leukemia Inhibitory Factor
-
Lymphokines / administration & dosage
-
Lymphokines / pharmacology*
-
Lymphokines / toxicity
-
Mice
-
Mice, Transgenic
-
Motor Neurons / drug effects*
-
Mutation / genetics
-
Mutation / physiology
-
Pilot Projects
-
Spinal Cord / pathology*
-
Superoxide Dismutase / genetics*
Substances
-
Growth Inhibitors
-
Interleukin-6
-
LIF protein, human
-
Leukemia Inhibitory Factor
-
Lif protein, mouse
-
Lymphokines
-
Superoxide Dismutase